Skip to main content

Table 1 Baseline characteristic of patients in treatment and control group

From: Efficacy of the Essential Amino Acids and Keto-Analogues on the CKD progression rate in real practice in Russia - city nephrology registry data for outpatient clinic

  Treatment group Control group p
Number of patients 96 96  
Diabetes mellitus type II 12/96 (13 %) 14/96 (14 %) p = 0.8
Polycystic kidney disease 6/96 (6 %) 8/96 (8 %) p = 0.6
Hypertension 23 (24 %) 20 (21 %) p = 0.6
Male/female 40/56 (42 %) 44/52 (46 %) p = 0.6
Age 54 ± 15 57 ± 13 p = 0.14
eGFR (CKD-EPI), ml/min/1.73 m2 23 ± 9 25 ± 11 p = 0.17
CKD stage 3B/4/5 28/43/25 (29 %/45 %/26 %) 33/37/26 (34 %/39 %/27 %) p = 0.6
Albumin, g/dl 4.1 ± 0.5 4.2 ± 0.4 p = 0.13
Calcium, mmol/l 2.28 ± 0.16 2.26 ± 0.14 p = 0.4
Phosphate, mmol/l 1,27 ± 0,26 1,21 ± 0,24 p = 0.10
Sodium, mmol/l 140 ± 3 141 ± 3 p = 0.02
Cholesterol, mmol/l 5.8 ± 1.2 5.5 ± 1.0 p = 0.06
Triglycerides, mmol/ 2.06 ± 0.98 1.85 ± 1.11 p = 0.19
Hemoglobin, g/dl 12.4 ± 1.4 12.2 ± 1.3 p = 0.3
Serum Fe, μmol/l 13 ± 5 12 ± 4 p = 0.13
CRP, mg/dl 0.1 ÷ 0.6 0.2 ÷ 0.8 p = 0.13
Mean proteinuria, g/day 1.18 ÷ 2.56 1.24 ÷ 2.42 p = 0.06
Maximal proteinuria, g/day 1.49 ÷ 4.94 1.56 ÷ 5.72 p = 0.11
Number of patients with hypertension (>140/90 mmHg) 31/96 (32 %) 34/96 (35 %) p = 0.5
Systolic blood pressure 137 ± 20 139 ± 22 p = 0.5
Diastolic blood pressure 83 ± 12 81 ± 11 p = 0.2